Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia

Michelle L. Churchman, Jonathan Low, Chunxu Qu, Elisabeth M. Paietta, Lawryn H. Kasper, Yunchao Chang, Debbie Payne-Turner, Mark J. Althoff, Guangchun Song, Shann Ching Chen, Jing Ma, Michael Rusch, Dan McGoldrick, Michael Edmonson, Pankaj Gupta, Yong Dong Wang, William Caufield, Burgess Freeman, Lie Li, John C. PanettaSharyn Baker, Yung Li Yang, Kathryn G. Roberts, Kelly McCastlain, Ilaria Iacobucci, Jennifer L. Peters, Victoria E. Centonze, Faiyaz Notta, Stephanie M. Dobson, Sasan Zandi, John E. Dick, Laura Janke, Junmin Peng, Kiran Kodali, Vishwajeeth Pagala, Jaeki Min, Anand Mayasundari, Richard T. Williams, Cheryl L. Willman, Jacob Rowe, Selina Luger, Ross A. Dickins, R. Kiplin Guy, Taosheng Chen, Charles G. Mullighan

Research output: Contribution to journalArticlepeer-review


Alterations of IKZF1, encoding the lymphoid transcription factor IKAROS, are a hallmark of high-risk acute lymphoblastic leukemia (ALL), however the role of IKZF1 alterations in ALL pathogenesis is poorly understood. Here, we show that in mouse models of BCR-ABL1 leukemia, Ikzf1 and Arf alterations synergistically promote the development of an aggressive lymphoid leukemia. Ikzf1 alterations result in acquisition of stem cell-like features, including self-renewal and increased bone marrow stromal adhesion. Retinoid receptor agonists reversed this phenotype, partly by inducing expression of IKZF1, resulting in abrogation of adhesion and self-renewal, cell cycle arrest, and attenuation of proliferation without direct cytotoxicity. Retinoids potentiated the activity of dasatinib in mouse and human BCR-ABL1 ALL, providing an additional therapeutic option in IKZF1-mutated ALL.

Original languageEnglish (US)
Pages (from-to)343-356
Number of pages14
JournalCancer cell
Issue number3
StatePublished - Sep 14 2015

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia'. Together they form a unique fingerprint.

Cite this